Tianjin Ringpu Bio-TechnologyLtd Past Earnings Performance
Past criteria checks 4/6
Tianjin Ringpu Bio-TechnologyLtd has been growing earnings at an average annual rate of 16.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 10% per year. Tianjin Ringpu Bio-TechnologyLtd's return on equity is 10.6%, and it has net margins of 19.7%.
Key information
16.4%
Earnings growth rate
12.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 10.0% |
| Return on equity | 10.6% |
| Net Margin | 19.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Tianjin Ringpu Bio-TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,339 | 460 | 562 | 177 |
| 31 Dec 23 | 2,249 | 453 | 555 | 172 |
| 30 Sep 23 | 2,195 | 387 | 548 | 182 |
| 30 Jun 23 | 2,170 | 385 | 531 | 160 |
| 31 Mar 23 | 2,136 | 355 | 518 | 143 |
| 01 Jan 23 | 2,084 | 347 | 507 | 132 |
| 30 Sep 22 | 1,985 | 354 | 555 | 105 |
| 30 Jun 22 | 1,875 | 349 | 530 | 113 |
| 31 Mar 22 | 1,838 | 369 | 511 | 114 |
| 01 Jan 22 | 2,007 | 413 | 547 | 117 |
| 30 Sep 21 | 2,038 | 438 | 522 | 124 |
| 30 Jun 21 | 2,117 | 454 | 548 | 120 |
| 31 Mar 21 | 2,106 | 441 | 552 | 116 |
| 31 Dec 20 | 2,000 | 398 | 551 | 111 |
| 30 Sep 20 | 1,895 | 302 | 549 | 102 |
| 30 Jun 20 | 1,737 | 255 | 527 | 97 |
| 31 Mar 20 | 1,613 | 224 | 495 | 94 |
| 31 Dec 19 | 1,467 | 194 | 440 | 94 |
| 30 Sep 19 | 1,346 | 158 | 399 | 89 |
| 30 Jun 19 | 1,260 | 137 | 373 | 84 |
| 31 Mar 19 | 1,203 | 124 | 373 | 79 |
| 31 Dec 18 | 1,190 | 119 | 360 | 80 |
| 30 Sep 18 | 1,179 | 108 | 371 | 81 |
| 30 Jun 18 | 1,157 | 117 | 301 | 123 |
| 31 Mar 18 | 1,112 | 112 | 321 | 105 |
| 31 Dec 17 | 1,047 | 105 | 343 | 85 |
| 30 Sep 17 | 1,008 | 136 | 341 | 61 |
| 30 Jun 17 | 993 | 138 | 402 | 0 |
| 31 Mar 17 | 988 | 140 | 398 | 0 |
| 31 Dec 16 | 970 | 133 | 391 | 0 |
| 30 Sep 16 | 943 | 129 | 357 | 0 |
| 30 Jun 16 | 905 | 113 | 364 | 0 |
| 31 Mar 16 | 832 | 108 | 337 | 0 |
| 31 Dec 15 | 793 | 110 | 334 | 0 |
| 30 Sep 15 | 690 | 68 | 330 | 0 |
| 30 Jun 15 | 639 | 43 | 340 | 0 |
| 31 Mar 15 | 625 | 34 | 346 | 0 |
| 31 Dec 14 | 585 | 27 | 327 | 0 |
| 30 Sep 14 | 669 | 95 | 323 | 0 |
| 30 Jun 14 | 676 | 113 | 304 | 0 |
| 31 Mar 14 | 722 | 140 | 299 | 0 |
| 31 Dec 13 | 755 | 152 | 302 | 0 |
| 30 Sep 13 | 724 | 149 | 271 | 0 |
| 30 Jun 13 | 702 | 148 | 263 | 0 |
Quality Earnings: 300119 has a large one-off gain of CN¥200.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300119's current net profit margins (19.7%) are higher than last year (16.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300119's earnings have grown by 16.4% per year over the past 5 years.
Accelerating Growth: 300119's earnings growth over the past year (29.4%) exceeds its 5-year average (16.4% per year).
Earnings vs Industry: 300119 earnings growth over the past year (29.4%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 300119's Return on Equity (10.6%) is considered low.